Cord Blood

Because cord blood present within a newborn’s umbilical is rich with stem cells, it can be collected and stored for future medical use.

How Stem Cell Treatments Can Ease Hip Injuries and Arthritis

February 1, 2022 By Cade Hildreth (CEO) 1 Comment

In addition to the use of stem cells for the treatment of cancer and other chronic diseases, stem cell treatments for hips are being now showing great promise.

Throughout time and across the world, people have aged into delicacy, and ultimately, decline. While death is a natural part of the human condition – the end any organism can expect eventually – it sometimes comes sooner than it needs. Even when it doesn’t, decline makes life more difficult and the body less sound. This hard fact has made the possibility of stem cell treatments for hips and other parts of the body appealing. [Read more…]

Cord Blood and Tissue Banking Market Dynamics in 2022

February 1, 2022 By Cade Hildreth (CEO) Leave a Comment

The first transplant using cord blood-derived hematopoietic stem cells was performed in October 1988. Since that year, remarkable achievements have been made in terms of research into umbilical cord blood-derived hematopoietic and progenitor cells. More than 40,000 UCB transplants (UCBTs) have been performed across different geographies of the world, in both children and adults, to treat diseases that include hematologic, metabolic, immunologic, neoplastic, and neurologic disorders. [Read more…]

How the Cord Blood and Tissue Market is Changing

January 17, 2022 By Cade Hildreth (CEO) Leave a Comment

The global cord blood and tissue banking market is consolidating, driven by the emergence of holding companies and aggressive M&A activity. This is creating risks for cord blood market participants, as well as new opportunities.

Serious threats to the industry include:

Low rates of stored cord blood utilization
Utilization of bone marrow and peripheral blood stem cells as alternative sources of stem cells for HSCT
Growing prevalence of haploidentical transplantation
Expensive transplant procedures, ranging from $200-300K
Difficulty educating Obstetricians about the future value of cellular therapies
Low rates of market penetration
Low rates of cord blood awareness among expectant parents

[Read more…]

Onk Therapeutics Secures $21.5M Series A for Cord Blood and iPSC-derived NK Cell therapies

January 17, 2022 By Cade Hildreth (CEO) Leave a Comment

$21.5M Series A financing round to advance pipeline of next-gen engineered off-the-shelf NK cell therapies
Funding round led by current investors Acorn Bioventures and ALSHC; joined by new investor Cormorant Asset Management
Financing will drive multiple pre-clinical programs through IND-enabling studies and the continued progression of a GMP manufacturing capability

[Read more…]

Cord Blood Banking in Latin America – Interview with James Mendez of Cryoholdco

January 16, 2022 By Cade Hildreth (CEO) Leave a Comment

In this interview with James Alexis Mendez, we discuss the market strategy of CryoHoldco, a stem cell bank holding company that is the market leader in Latin America and one of the ten largest cord blood banks in the world. James Alexis Mendez currently serves as the CFO and Board member of CryoHoldco.

Approaching 200,000 stem cell units in storage, CryoHoldco is more than 5X larger than any other stem cell bank in Latin America. CryoHoldco owns the cord blood market leaders in both Mexico and Colombia, and plans to expand into other regions of Latin America. [Read more…]